This research demonstrates how para-substituent modifications enhance magnetic properties in dinuclear dysprosium complexes, indicating new possibilities for molecular magnets.
Strategic modulation of the local ligand field via substituent effects provides a precise approach to enhancing magnetic anisotropy in lanthanide-based molecular magnets. We report two dinuclear dysprosium(III) complexes, ([Dy2(μ-CA)(bbpen-Cl)2]·MeCN) (1) and ([Dy2(μ-CA)(bbpen)2]·MeCN·2H2O) (2), bridged by a chloranilate (CA2–) ligand. Replacing the electron-withdrawing para-chloro substituent on the phenolate donors in 1 with a hydrogen atom in 2 profoundly tunes the crystal field. This seemingly subtle chemical modification induces a rigorous geometric evolution from a D2d-distorted triangular dodecahedron in 1 toward a more highly symmetric D4d square antiprism in 2. More critically, the removal of the inductive electron-withdrawing effect (-I effect) of the chlorine atoms enhances the electron density on the axial phenolate oxygen atoms in 2, significantly strengthening the axial crystal field. This results in a 72% increase in the effective energy barrier for magnetization reversal, from Ueff/kB = 573(10) K for 1 to Ueff/kB = 987(48) K for 2. Concurrently, under an optimal 2000 Oe DC field, the QTM(quantum tunneling of magnetization) relaxation time is extended by a factor of approximately 12.5 compared to zero field, and the magnetic blocking temperature (TB) is elevated to 6.16 K. Ab initio calculations revealing that the H-substituted framework in 2 not only maintains a higher purity of the Ising-type ground state but also preserves strict axiality across the first three excited states, with the principal magnetic axis reorienting by less than 4° relative to the ground state, effectively quenching thermally assisted QTM (TA-QTM) pathways. Significant transverse character only emerges at a higher-lying excited state whose energy exceeds 900 K. This work unequivocally demonstrates that para-substituent engineering is a potent and rational strategy for surmounting established performance barriers in polynuclear SMMs.
No takes yet. Share an insight, caveat, or question.
Qu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: